GAMMACAN REPORTS PRE-IND MEETING WITH FDA REGARDING VITIGAM
GammaCan International has met with the FDA to discuss requirements for the filing of an investigational new drug (IND) application for VitiGam, the company's second-generation investigational treatment for metastatic melanoma.
GammaCan is planning to initiate human clinical trials with VitiGam. Research has shown that plasma from donors with vitiligo, a benign condition affecting skin pigmentation, has anti-melanoma properties. Based on these and other findings, the company recently held a pre-IND meeting with the FDA.